Emerging concepts in the epidemiology, pathophysiology, and clinical care of osteoporosis across the menopausal transition

Abstract

Bone loss in women accelerates during perimenopause, and continues into old age. To-date, there has been little progress made in stratifying for fracture risk in premenopausal and early postmenopausal women. Epidemiologic data suggests that changes in serum FSH could predict decrements in bone mass during peri- and postmenopause. In bone, FSH stimulates osteoclast formation by releasing osteoclastogenic cytokines. Here, we address the evidence for bone loss across the menopausal transition, discuss strategies for detection and treatment of early postmenopausal osteoporosis, and describe the role FSH plays in physiology and likely in pathophysiology of early postmenopausal bone loss.

Keywords: Bone mineral density; Follicle-stimulating hormone; Menopause; Monoclonal antibodies; Osteoporosis; Polyclonal antibodies.